<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116119">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02079168</url>
  </required_header>
  <id_info>
    <org_study_id>RXI-109-1401</org_study_id>
    <nct_id>NCT02079168</nct_id>
  </id_info>
  <brief_title>A Multi-Center, Prospective, Randomized, Single-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults</brief_title>
  <official_title>A Multi-Center, Prospective, Randomized, Single-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RXi Pharmaceuticals, Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RXi Pharmaceuticals, Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation
      following elective keloid excision.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction in the recurrence of a keloid after keloid excision</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of RXI-109</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess severity and frequency of reported adverse events and clinically-relevant changes in laboratory testing after elective excision of a keloid</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Keloid</condition>
  <arm_group>
    <arm_group_label>RXI-109 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin at the time of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RXI-109 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin two weeks after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RXI-109 Cohort 1</intervention_name>
    <description>Intradermal administration of RXI-109 at the site of one excised keloid and a placebo comparator at the site of a second excised keloid. Dosing to begin at the time of surgery.</description>
    <arm_group_label>RXI-109 Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RXI-109 Cohort 2</intervention_name>
    <description>Intradermal administration of RXI-109 at the site of one excised keloid and a placebo comparator at the site of a second excised keloid. Dosing to begin two weeks after surgery.</description>
    <arm_group_label>RXI-109 Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults, 21-55 years of age.

          -  Two keloids of approximately similar size and anatomical location on the earlobe,
             neck, or torso.

          -  Keloids to be excised must have been present for &gt; 1 year.

        Exclusion Criteria:

          -  Use of tobacco or nicotine-containing products

          -  Pregnant or lactating

          -  Post-menopausal or full hysterectomy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Pavco, PhD</last_name>
    <role>Study Director</role>
    <affiliation>RXi Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manager, Clinical Operations</last_name>
    <email>clinicaloperations@rxipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 21, 2014</lastchanged_date>
  <firstreceived_date>March 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keloid</keyword>
  <keyword>Cicatrix</keyword>
  <keyword>Keloid prevention</keyword>
  <keyword>Keloid revision/excision</keyword>
  <keyword>Keloidectomy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keloid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
